After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Dr. Reddy’s Laboratories (NYSE:RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...